Overview
Enzymes are a class of protein catalysts that facilitate biochemical reactions in living organisms. By significantly reducing the activation energy required for reactions, enzymes accelerate the conversion of substrate molecules into product molecules without being consumed in the process. They play an indispensable role in nearly all physiological processes, including metabolism, DNA replication, signal transduction, and detoxification, and are widely present in various tissues and cell types throughout the human body.
Due to their central role in regulating biological functions, dysfunction or dysregulation of enzymes is closely associated with numerous human diseases, including cancer, neurodegenerative disorders, inflammatory diseases, and metabolic syndromes. Enzymes have therefore become important targets for drug development, as well as key tools in clinical diagnostics and industrial biotechnology. Currently, enzyme inhibitors such as kinase inhibitors, protease inhibitors, and reverse transcriptase inhibitors have been successfully developed for the treatment of cancers, viral infections, cardiovascular diseases, and other conditions.
Subcategories
KinasesKinasesKinases are a class of enzymes that catalyze the transfer of phosphate groups from high-energy donor molecules (such as ATP) to specific substrate molecules. Protein kinases constitute the largest subfamily, regulating target protein activity, localization, and interactions through phosphorylation, and play central roles in signal transduction, cell cycle control, metabolic regulation, and gene expression. The human genome encodes more than 500 protein kinases, accounting for approximately 2% of all protein-coding genes. Dysregulation or mutation of protein kinases is closely associated with various human diseases, including cancer, inflammatory disorders, neurodegenerative diseases, and metabolic syndromes. It is estimated that approximately 30% of all human cancers harbor kinase mutations or overexpression. Consequently, kinases have become the second largest drug target family after GPCRs. To date, more than 80 small-molecule kinase inhibitors have been approved by the FDA for the treatment of various cancers, autoimmune diseases, and inflammatory disorders. Recombinant kinase proteins serve as indispensable tools in drug screening, target validation, and structure-function studies.
>> View productsOthers EnzymesOthers Enzymes>> View productsTry another keyword, SKU, CAS number, or product category.
